Fibrates are PPARα modulators used for hyperlipidemia therapy and are represented by fenofibrate and pemafibrate, whereas thiazolidinediones, such as pioglitazone and rosiglitazone, are used for the treatment of diabetes through PPARγ agonism [14,94]. This evidence concerns the gene PPARG and hyperlipidemia.